Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data
March 02, 2011
Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data
A company spokesperson could not verify that the company will definitely discuss pharmacogenomics data on Avastin at the June 28-29 hearing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter - FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter - FDA Rejects Avastin as Breast Cancer Drug; Genentech to Conduct New Trial to ID Best Responders
November 30, 2011 / Pharmacogenomics Reporter - New VEGF Biomarker Data Illustrates Complexities of Personalizing Anti-Angiogenic Drugs
September 28, 2011 / Pharmacogenomics Reporter - NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer
February 23, 2011 / Pharmacogenomics Reporter